Within the symptomatic group of C9+ carriers, there were no significant differences in global metrics (network density, mean connection strength, clustering coefficient, path length, and modularity) between the nine patients with ALS alone and the nine patients with bvFTD or ALS-FTD. This evidence concerns the gene C9 and amyotrophic lateral sclerosis.